Skip to search formSkip to main contentSkip to account menu

PDGFR alpha/KIT Mutant-specific Inhibitor BLU-285

Known as: BLU-285 
An orally bioavailable inhibitor of specific mutated forms of platelet-derived growth factor receptor alpha (PDGFR alpha; PDGFRa) and mast/stem cell… 
National Institutes of Health

Related topics

Related topics

2 relations
NCIt Antineoplastic Agent TerminologyReceptor Tyrosine Kinase Inhibition

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Rapid Responses to Avapritinib (BLU-285) in Mastocytosis.
In a phase I trial of avapritinib (formerly BLU-285), which targets D816V mutant KIT, for the treatment of advanced systemic… 
2018
2018
BLU-285 Targets KIT/PDGFRA Conformation and Activating Loop Mutations.
The small-molecule inhibitor BLU-285 inhibits clinically relevant KIT and PDGFRA mutations. 
2017
2017
Clinical activity of BLU-285 in advanced gastrointestinal stromal tumor (GIST).
11011Background: Oncogenic mutations in KIT or PDGFRα drive > 85% of GIST. However, primary and acquired mutations in the… 
Review
2017
Review
2017
Targeting deubiquitinases in CLL.
BACKGROUND Asparaginase (ASNase) is an integral part of therapy for pediatric acute lymphoblastic leukemia (ALL). Pegylated E… 
2017
2017
Abstract 2081: Robust activity of BLU-285, a potent and highly selective inhibitor of mutant KIT and PDGFRα, in patient-derived xenograft (PDX) models of gastrointestinal stromal tumor (GIST)
Objective: Patients with advanced and treatment-resistant GIST are treated with tyrosine kinase inhibitors (TKI) such as imatinib… 
2016
2016
Preliminary safety and activity in a first-in-human phase 1 study of BLU-285, a potent, highly-selective inhibitor of KIT and PDGFRα activation loop mutants in advanced gastrointestinal stromal tumor…
2016
2016
Inhibitory Effects of Midostaurin and Blu-285 on Myeloid Progenitor Cells Derived from Patients with Multi-Mutated KIT D816V+ Advanced Systemic Mastocytosis
Recent data have highlighted that the molecular pathogenesis of advanced systemic mastocytosis (advSM) is complex. In addition to… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)